

Gull Global Ltd
Form 4
February 05, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Gull Global Ltd

(Last) (First) (Middle)

PO BOX N-4899, 2/F BAHAMAS
FINANCIAL CTR, SHIRLEY &
CHARLOTTE STREETS

(Street)

NASSAU, C5 BH1-1000

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
USANA HEALTH SCIENCES INC
[USNA]

3. Date of Earliest Transaction
(Month/Day/Year)
02/01/2019

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D) Price			
Common Stock	02/01/2019		S ⁽¹⁾		8,662	D	\$ 114.34 (2) (3)	9,886,952 (11)	D
Common Stock	02/01/2019		S ⁽¹⁾		2,910	D	\$ 115.57 (3) (4)	9,884,042	D
Common Stock	02/01/2019		S ⁽¹⁾		8,354	D	\$ 116.2 (3) (5)	9,875,688	D
Common	02/01/2019		S ⁽¹⁾		719	D	\$	9,874,969	D

Edgar Filing: Gull Global Ltd - Form 4

Stock						116.97 (3) (6)		
Common Stock	02/04/2019	S(1)	1,400	D	\$	114.19 (3) (7)	9,873,569	D
Common Stock	02/04/2019	S(1)	2,600	D	\$	115.32 (3) (8)	9,870,969	D
Common Stock	02/04/2019	S(1)	4,555	D	\$	116.32 (3) (9)	9,866,414	D
Common Stock	02/04/2019	S(1)	800	D	\$ 116.9 (3) (10)		9,865,614	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Gull Global Ltd PO BOX N-4899, 2/F BAHAMAS FINANCIAL CTR SHIRLEY & CHARLOTTE STREETS NASSAU, C5 BH1-1000	Director 10% Owner Officer Other
	X

Signatures

/s/ Valarie A. Hing, Attorney
in Fact

02/05/2019

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) Weighted average price. Price range in multiple transactions was \$113.94 to \$114.93, inclusive.
- (3) The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff of the Securities Exchange Commission information regarding the number of shares sold at each price within the ranges set forth.
- (4) Weighted average price. Price range in multiple transactions was \$114.94 to \$115.93, inclusive.
- (5) Weighted average price. Price range in multiple transactions was \$115.94 to \$116.80, inclusive.
- (6) Weighted average price. Price range in multiple transactions was \$116.94 to \$117.10, inclusive.
- (7) Weighted average price. Price range in multiple transactions was \$113.70 to \$114.68, inclusive.
- (8) Weighted average price. Price range in multiple transactions was \$114.82 to \$115.81, inclusive.
- (9) Weighted average price. Price range in multiple transactions was \$115.82 to \$116.76, inclusive.
- (10) Weighted average price. Price range in multiple transactions was \$116.82 to \$117.00, inclusive.

- The total number of outstanding shares reflects 300 shares fewer than the total number of shares last reported as beneficially owned on a
- (11) Form 4 filed on January 4, 2019, which 300 shares were sold on January 4, 2019, at an average weighted price of \$115.00, with actual prices ranging from \$114.71 to \$115.67 (and were in addition to the sales reported on the Form 4 filed on January 4, 2019).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.